UNLOCKING SECRETS TO TREAT DISEASES
Epitracker uses metabolomics and big data analytics to discover novel small molecule therapeutics across the following four primary discovery programs:
In addition to learning (below) about how we make these discoveries , you can also read more about specific conditions we are targeting to improve human and animal health.
Discovery Pipeline: Smart-Screened Compound Libraries
Our discovery process starts with the analysis of more than one million metabolomic, lipid, and clinical data points across unique patient populations using multiple statistical models to prioritize small molecules. This prioritization is based on each molecule's potential as a biomarker, therapeutic target, and candidate therapeutic across our four discovery programs. These 'smart screened' molecules become part of Epitracker's rapidly expanding compound libraries that are then made available for further development.
Discovery to Development Pipeline
Promising, smart-screened small molecules are advanced through Epitracker's discovery-to-development pipeline. As these molecules advance, Epitracker seeks industry partners to meet regulatory milestones and successfully commercialize new healthcare products aimed to improve global health.